• Not yet recruiting

NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)

NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-3)

(MonumenTAL-5

NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-3)


The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab in combination with pomalidomide and dexamethasone (DPd).


Sponsor

Janssen Research & Development, LLC

 

ClinicalTrials.gov Identifier: NCT05455320

Official Title: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy

First Posted : July 13, 2022

Click here to see details on ClinicalTrials.gov

 

Talquetamab

Talquetamab (Code C171840)

Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564

GPRC5D x CD3 Bispecific Antibody JNJ-64407564

GPRC5D x CD3 DuoBody Antibody JNJ-64407564

GPRC5D/CD3 DuoBody Antibody JNJ-64407564

Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564

JNJ 64407564

JNJ-64407564

JNJ64407564

Talquetamab

TALQUETAMAB

 

Drug: Talquetamab

Drug: Daratumumab

Drug: Pomalidomide

Drug: Dexamethasone

 

Locations

United States, Arizona

United States, Arkansas

United States, California

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Kansas

United States, Louisiana

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Mississippi

United States, Missouri

United States, New York

United States, North Carolina

United States, Ohio

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Virginia

United States, Washington

Asia

Europe

Belgium

Brazil

China

Czechia

France

Germany

Greece

Israel

Italy

Japan

Korea, Republic of

Netherlands

Poland

Spain

Taiwan

Turkey

United Kingdom

 

RELATED POSTS


TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

Click here for details


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

Click here for details


NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)

Click here for details


NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)

Click here for details


NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Click here for details


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Click here for details

 

TALQUETAMAB STUDIES:


NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

Click here for details


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

Click here for details

Posts Archive